As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.

The European Court of Justice has decided that organisms made with precision techniques such as CRISPR will be subject to the same rules as transgenic plants or animals.

The plan would also allow non-EU countries to pay to participate in EU research programs, albeit without wielding “decisional power.”

The increase is associated with travel to Europe, where large outbreaks are occurring.

The budget is smaller than what some researchers hoped for, and too high for at least one EU member state.

The pesticides, which studies show are harmful to bees, will be prohibited in open fields by the end of 2018.

Despite some difficult negotiations, academic institutions in the Netherlands have been securing subscriptions that combine publishing and reading into one fee.

Alzheimer’s researcher John Hardy calls the departure “an unmitigated disaster” for science and healthcare in Britain.

Crops produced using mutagenic technologies such as CRISPR should generally be exempt from regulatory laws governing GMOs, according to the published opinion.